The European Market Access Lag: 2021–2024
Pharmaceutical Technology
JUNE 9, 2025
On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.
Let's personalize your content